


## Fenoverine-d<sub>8</sub>

<b>Cat. No.:</b>	HY-107349S
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>17</sub> D <sub>8</sub> N <sub>3</sub> O <sub>3</sub> S
<b>Molecular Weight:</b>	467.61
<b>Target:</b>	Calcium Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Fenoverine-d <sub>8</sub> is the deuterium labeled Fenoverine[1]. Fenoverine (Spasmopriv) is an antispasmodic agent and inhibits calcium channel currents[2]. Fenoverine induces rhabdomyolysis[3].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. J Mironneau, et al. Fenoverine inhibition of calcium channel currents in single smooth muscle cells from rat portal vein and myometrium. *Br J Pharmacol*. 1991 Sep;104(1):65-70.
- [3]. Chung-Wen Chen, et al. Rhabdomyolysis induced by fenoverine: a case report and literature review. *Acta Neurol Taiwan*. 2005 Sep14(3):143-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA